JP2024125338A5 - - Google Patents

Download PDF

Info

Publication number
JP2024125338A5
JP2024125338A5 JP2024098452A JP2024098452A JP2024125338A5 JP 2024125338 A5 JP2024125338 A5 JP 2024125338A5 JP 2024098452 A JP2024098452 A JP 2024098452A JP 2024098452 A JP2024098452 A JP 2024098452A JP 2024125338 A5 JP2024125338 A5 JP 2024125338A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
groups
alkanediyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024098452A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024125338A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/032292 external-priority patent/WO2019222269A1/en
Application filed filed Critical
Publication of JP2024125338A publication Critical patent/JP2024125338A/ja
Publication of JP2024125338A5 publication Critical patent/JP2024125338A5/ja
Pending legal-status Critical Current

Links

JP2024098452A 2018-05-14 2024-06-19 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド Pending JP2024125338A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862671047P 2018-05-14 2018-05-14
US62/671,047 2018-05-14
PCT/US2019/032292 WO2019222269A1 (en) 2018-05-14 2019-05-14 Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway
JP2020564427A JP7508375B2 (ja) 2018-05-14 2019-05-14 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020564427A Division JP7508375B2 (ja) 2018-05-14 2019-05-14 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド

Publications (2)

Publication Number Publication Date
JP2024125338A JP2024125338A (ja) 2024-09-18
JP2024125338A5 true JP2024125338A5 (https=) 2025-03-24

Family

ID=67002352

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564427A Active JP7508375B2 (ja) 2018-05-14 2019-05-14 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド
JP2024098452A Pending JP2024125338A (ja) 2018-05-14 2024-06-19 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020564427A Active JP7508375B2 (ja) 2018-05-14 2019-05-14 熱ショックタンパク質経路に関連する疾患の治療のための、修飾された糖基を有するビアリールアミド

Country Status (18)

Country Link
US (2) US11827664B2 (https=)
EP (1) EP3794009A1 (https=)
JP (2) JP7508375B2 (https=)
KR (1) KR20210021457A (https=)
CN (2) CN119285591A (https=)
AU (2) AU2019271126B2 (https=)
BR (1) BR112020023277A2 (https=)
CA (1) CA3100333A1 (https=)
CL (1) CL2020002957A1 (https=)
CO (1) CO2020015380A2 (https=)
EA (1) EA202092727A1 (https=)
IL (2) IL309891B2 (https=)
MX (2) MX2020012366A (https=)
PE (1) PE20211917A1 (https=)
PH (1) PH12020551941A1 (https=)
SG (1) SG11202011311YA (https=)
UA (1) UA130486C2 (https=)
WO (1) WO2019222269A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013119985A1 (en) 2012-02-09 2013-08-15 University Of Kansas C-terminal hsp90 inhibitors
KR20210021457A (ko) 2018-05-14 2021-02-26 리아타 파마슈티컬즈, 아이엔씨. 열충격 단백질 경로와 연관된 질환의 치료를 위한 변형된 당기를 가진 바이아릴 아마이드
KR102551319B1 (ko) 2018-05-14 2023-07-05 길리애드 사이언시즈, 인코포레이티드 Mcl-1 억제제
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
AU2020391106B2 (en) 2019-11-26 2024-03-21 Gilead Sciences, Inc. Processes and intermediates for preparing MCL1 inhibitors
WO2022108984A1 (en) 2020-11-19 2022-05-27 Gilead Sciences, Inc. Processes and intermediates for preparing macrocyclic mcl1 inhibitors
WO2023039293A1 (en) * 2021-09-13 2023-03-16 Rubedo Life Sciences, Inc. Coumarin derivatives of sugar analogs and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06501465A (ja) 1990-09-07 1994-02-17 シェリング・コーポレーション 抗ウイルス化合物
DE19512886A1 (de) 1995-04-06 1996-10-10 Bayer Ag Substituierte Cycloalkene
FR2792320B1 (fr) 1999-04-19 2003-05-09 Hoechst Marion Roussel Inc Nouveaux amides aromatiques substitues par un ribose, leur procede de preparation et leur application comme medicaments
EP1344780A4 (en) 2000-11-30 2004-01-28 Kissei Pharmaceutical GLUCOPYRANOSYLOXYBENZYLBENZOLE DERIVATIVES, MEDICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION
JP4263095B2 (ja) 2001-09-21 2009-05-13 ノバルティス アクチエンゲゼルシャフト Aceおよびnepの両阻害剤としてのピラン誘導体
US7208630B2 (en) 2004-10-27 2007-04-24 University Of Kansas Heat shock protein 90 inhibitors
WO2010096650A1 (en) 2009-02-20 2010-08-26 University Of Kansas Novobiocin analogues having modified sugar moieties
WO2006050501A2 (en) 2004-11-03 2006-05-11 University Of Kansas Novobiocin analogues as anticancer agents
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
US8212012B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
US8212011B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
WO2007025943A2 (en) 2005-08-30 2007-03-08 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
CA2669687C (en) 2006-11-15 2013-09-10 Forest Laboratories Holdings Limited Phthalazine derivatives
DE102007002715A1 (de) * 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
KR101313804B1 (ko) 2007-03-20 2013-10-01 쿠리스 인코퍼레이션 Hsp90 억제제로서의 융합된 아미노 피리딘
US7960353B2 (en) 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
SG187502A1 (en) 2008-02-01 2013-02-28 Takeda Pharmaceutical Oxim derivatives as hsp90 inhibitors
FR2928645A1 (fr) 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2010014617A1 (en) 2008-07-28 2010-02-04 University Of Kansas Heat shock protein 90 inhibitor dosing methods
WO2011041593A1 (en) 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
US20130116227A1 (en) 2010-07-13 2013-05-09 Dainippon Sumitomo Pharma Co., Ltd. Biaryl amide derivative or pharmaceutically acceptable salt thereof
CN103596955B (zh) 2011-04-05 2016-11-16 索隆-基特林癌症研究协会 Hsp90抑制剂
WO2012162054A1 (en) 2011-05-20 2012-11-29 The University Of Kansas Dynamic inhibitors of heat shock protein 90
WO2013112548A1 (en) 2012-01-23 2013-08-01 University Of South Florida Gamma-aapeptides with potent and broad-spectrum antimicrobial activity
WO2013119985A1 (en) 2012-02-09 2013-08-15 University Of Kansas C-terminal hsp90 inhibitors
US9422230B2 (en) 2013-05-09 2016-08-23 Council Of Scientific And Industrial Research Process for the preparation of an anticonvulsant agent pregabalin hydrochloride
EP3066072B1 (en) 2013-11-07 2021-11-03 The University of Kansas Biphenylamide derivative hsp90 inhibitors
EP3068778B1 (en) 2013-11-11 2025-02-19 The University of Kansas Coumarin based hsp90 inhibitors with urea and ether substituents
AU2015274265B2 (en) 2014-06-13 2020-05-21 The University Of Kansas Triazole modified coumarin and biphenyl amide-based Hsp90 inhibitors
CN106536498A (zh) 2014-06-24 2017-03-22 堪萨斯大学 作为hsp90抑制剂和hsp70诱导剂的具有经修饰醚基的联苯酰胺
KR20210021457A (ko) 2018-05-14 2021-02-26 리아타 파마슈티컬즈, 아이엔씨. 열충격 단백질 경로와 연관된 질환의 치료를 위한 변형된 당기를 가진 바이아릴 아마이드

Similar Documents

Publication Publication Date Title
JP2024125338A5 (https=)
US9795606B2 (en) Pyrrolopyrimidine compounds for the treatment of cancer
ES2525820T3 (es) Derivados del ácido hidroxámico N-enlazados útiles como agentes antibacterianos
ES2213373T3 (es) Nuevas benzotiepinas que tienen actividad como inhibidores del transporte del acido biliar ileal y de la absorcion de taurocolato.
AU2021208027B2 (en) Substituted triazinones as thyroid hormone receptor agonists
AU774664B2 (en) Amine derivatives as protease inhibitors
JP2021534124A5 (https=)
DE69521208T2 (de) Morpholinderivate und ihre verwendung als therapeutische mittel
TW201920129A (zh) 化合物、組合物及方法
CN102216307B (zh) 含氮杂环化合物及其制备和作为抗菌药剂的用途
US20080070866A1 (en) Chemical compounds
JP2007515432A5 (https=)
AU2003214394A1 (en) Derivatives of 4-(imidazol-5-YL)-2-(4-sulfoanilino) pyrimidine with CDK inhibitory activity
SK13322001A3 (sk) Tetrahydropyránové deriváty, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie
WO2009141090A9 (en) {f-19} -labeled l-glutamic acid and l-glutamine derivative (iii), use thereof and method for obtaining them
EP4149927A1 (en) Enpp1 modulators and uses thereof
CN116947903A (zh) 补体因子的抑制剂和其用途
EP4359405A1 (en) Beta-lactam derivatives for the treatment of diseases
JP2024546678A5 (https=)
ZA200308392B (en) Chemical compounds and pharmaceutical compositions as cathepsin S inhibitors.
AU2024210744A1 (en) Inhibitors of mptp
CN1289248A (zh) 治疗或预防肺病毒感染及有关疾病的化合物、组合物和方法
TW200804358A (en) Novel compound having heterocycle
TW200528420A (en) Amino acids with affinity for the α-2-δ-subunit of calcium channel
EP3040329A1 (en) Novel aromatic compound and use thereof